ATE320802T1 - Fettsäure-analoge zur behandlung von krebs - Google Patents

Fettsäure-analoge zur behandlung von krebs

Info

Publication number
ATE320802T1
ATE320802T1 AT01952065T AT01952065T ATE320802T1 AT E320802 T1 ATE320802 T1 AT E320802T1 AT 01952065 T AT01952065 T AT 01952065T AT 01952065 T AT01952065 T AT 01952065T AT E320802 T1 ATE320802 T1 AT E320802T1
Authority
AT
Austria
Prior art keywords
sub
alkyl
fatty acid
treating cancer
acid analogues
Prior art date
Application number
AT01952065T
Other languages
English (en)
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Application granted granted Critical
Publication of ATE320802T1 publication Critical patent/ATE320802T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01952065T 2000-07-13 2001-07-13 Fettsäure-analoge zur behandlung von krebs ATE320802T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20003591A NO20003591L (no) 2000-07-13 2000-07-13 Fettsyreanaloger for behandling av kreft

Publications (1)

Publication Number Publication Date
ATE320802T1 true ATE320802T1 (de) 2006-04-15

Family

ID=19911376

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01952065T ATE320802T1 (de) 2000-07-13 2001-07-13 Fettsäure-analoge zur behandlung von krebs

Country Status (17)

Country Link
US (1) US7378443B2 (de)
EP (1) EP1313463B1 (de)
JP (1) JP2004502732A (de)
KR (2) KR100861428B1 (de)
CN (1) CN100569228C (de)
AT (1) ATE320802T1 (de)
AU (2) AU7286001A (de)
BR (1) BR0112399A (de)
CA (1) CA2414480A1 (de)
DE (1) DE60118198T2 (de)
ES (1) ES2261441T3 (de)
MX (1) MXPA02012944A (de)
NO (2) NO20003591L (de)
NZ (1) NZ523316A (de)
RU (1) RU2283105C2 (de)
WO (1) WO2002003983A1 (de)
ZA (1) ZA200210028B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
AU2003278602C1 (en) 2002-06-20 2010-08-12 Pronova Biopharma Norge As Sulfur-containing phospholipid derivatives
JP2008506773A (ja) 2004-07-19 2008-03-06 ティア メディカ アクスイェ セルスカプ タンパク質材料と非酸化性脂肪酸体を含む組成物
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (de) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Vorrichtung zur messung der konzentration eines gelösten stoffs und entsprechende verfahren
US8758323B2 (en) 2009-07-30 2014-06-24 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
AU2014228387B2 (en) 2013-03-11 2016-09-01 Sciadonics, Inc. Lipid compositions containing bioactive fatty acids
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
DE102014116958B9 (de) * 2014-11-19 2017-10-05 Trumpf Laser- Und Systemtechnik Gmbh Optisches System zur Strahlformung eines Laserstrahls, Laserbearbeitungsanlage, Verfahren zur Materialbearbeitung und Verwenden einer gemeinsamen langgezogenen Fokuszone zur Lasermaterialbearbeitung
KR20180027516A (ko) * 2015-06-11 2018-03-14 유니버시티 오브 마이애미 암 치료 및 진단
CN105498622B (zh) * 2015-12-10 2017-10-17 江南大学 一种含硒表面活性剂及其制备方法和应用
CN107235880B (zh) * 2017-06-30 2018-10-30 江南大学 一种含硒阳离子表面活性剂及其应用
GB201910644D0 (en) * 2019-07-25 2019-09-11 Coegin Pharma As Cancer Treatment
AU2020405068A1 (en) 2019-12-18 2022-07-07 Stinginn Llc Substituted 1,2, 4-triazoles and methods of use
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
CN115260964A (zh) * 2022-08-29 2022-11-01 烟台市福山义昌精细化工厂 一种石油油管丝扣专用密封胶及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0686377B2 (ja) * 1985-09-30 1994-11-02 日清製粉株式会社 がん転移抑制剤
SE9103572D0 (sv) * 1991-11-29 1991-11-29 Astra Ab Organic salts of n,n'-diacetyl cystine
JPH0797320A (ja) * 1993-08-04 1995-04-11 Takuma Sasaki 制癌剤
US6358915B1 (en) * 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
AU693682B2 (en) * 1995-04-10 1998-07-02 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitor
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
DE69726182T2 (de) * 1996-12-11 2004-08-12 Dana-Farber Cancer Institute, Inc., Boston Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
DE19700774A1 (de) * 1997-01-13 1998-07-16 Hoechst Ag Antiadhäsive Sulfatid-Mimetika
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP4993878B2 (ja) * 2005-06-28 2012-08-08 ダイキョーニシカワ株式会社 多気筒エンジンの吸気装置

Also Published As

Publication number Publication date
NZ523316A (en) 2004-09-24
DE60118198T2 (de) 2007-01-25
BR0112399A (pt) 2003-05-27
KR20030016399A (ko) 2003-02-26
NO324634B1 (no) 2007-11-26
WO2002003983A1 (en) 2002-01-17
US7378443B2 (en) 2008-05-27
CN1441671A (zh) 2003-09-10
JP2004502732A (ja) 2004-01-29
ZA200210028B (en) 2004-01-26
MXPA02012944A (es) 2004-05-17
NO20003591L (no) 2002-01-14
US20040024063A1 (en) 2004-02-05
AU7286001A (en) 2002-01-21
CA2414480A1 (en) 2002-01-17
DE60118198D1 (de) 2006-05-11
ES2261441T3 (es) 2006-11-16
CN100569228C (zh) 2009-12-16
KR100861428B1 (ko) 2008-10-02
RU2283105C2 (ru) 2006-09-10
NO20025930L (no) 2003-01-13
AU2001272860B2 (en) 2005-11-24
NO20003591D0 (no) 2000-07-13
NO20025930D0 (no) 2002-12-11
EP1313463A1 (de) 2003-05-28
KR20080071598A (ko) 2008-08-04
HK1057473A1 (zh) 2004-04-08
EP1313463B1 (de) 2006-03-22

Similar Documents

Publication Publication Date Title
DE60118198D1 (de) Fettsäure-analoge zur behandlung von krebs
ATE306916T1 (de) Neue fettanaloge zur behandlung von sekundärer restenose
MX9804105A (es) Antagonistas de taquicininas a base de piperidonas.
RU2002134754A (ru) Аналоги жирных кислот для лечения рака
ATE238981T1 (de) Antitumorwirkstoffe
WO2004084812A3 (en) Tamandarin analogs and fragments thereof and methods of making and using
JP2004502732A5 (de)
ATE418974T1 (de) Fettsäure-analogen zur behandlung proliferierender hautstörungen
DE69839781D1 (en) Heterocyclische topoisomerase toxine
AU2003300385A8 (en) Anticancer compounds
WO2004080408A3 (en) Method of treating cancer with azaspirane compositions
DE69637283D1 (de) Analoge von n-acetylardeemin, verfahren zur herstellung und verwendung dieser analogen
DE60308171D1 (de) Haarpflegemittel, die phenolische haarformungsmittel enthalten
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis
MXPA05003909A (es) Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer.
ATE430476T1 (de) Schlammbehandlung
SE9800932D0 (sv) New compunds
KR940005541A (ko) 치환된 벤조에이트 유도체

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties